Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 20, 2009

High Throughput Genomics and Roche Join Forces for Advanced Gene-Expression Analysis Solution

  • High Throughput Genomics (HTG) is supplementing its service capabilities through a supply agreement with Roche Nimblegen. The firm will provide HTG with high density, multiplex DNA microarray slides for advanced gene-expression analysis.

    HTG will apply its quantitative nuclease protection assay (qNPA) process to the microarrays to enable researchers to quickly and efficiently measure the gene-expression levels in a variety of sample types. Sample preparation using qNPA technology allows for a simpler, more cost-effective workflow versus traditional labeling methods, according to HTG. The Roche NimbleGen multiplex technology offers a cost-effective high-density microarray providing in-depth gene-expression information, the company adds.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »